Medable, a leading provider of clinical trial technology, has once again secured the “Best Digital Health Solution” award at the Prix Galien UK Forum. This is the second consecutive year the company has received this recognition for its innovative platform, PALO ALTO.

Medable’s platform has gained widespread trust among major pharmaceutical companies and CROs, including 14 of the world’s top 20 pharmaceutical giants. Customers using Medable’s platform have reported remarkable outcomes, such as accelerated enrollment by 200% and cost reductions of 50%.

“This award is a testament to our unwavering commitment to transforming drug development,” said Medable CEO and co-founder Dr. Michelle Longmire. “We are eager to continue collaborating with industry leaders and partners to accelerate the process of bringing scientific discoveries to patients.”

The Prix Galien Awards, organized by The Galien Foundation, honor groundbreaking advancements in life sciences innovation. The Galien Foundation celebrates excellence in scientific discovery and innovation that enhance human health. It orchestrates the Prix Galien, an international program recognizing the development of innovative medicines with chapters worldwide. The Prix Galien holds a prestigious reputation, akin to the Nobel Prize in biopharmaceutical research.

Source link: http://www.businesswire.com/news/home/20240607926468/en/Medable-Wins-2024-Prix-Galien-UK-Award-for-Best-Digital-Health-Solution

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.